EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mitotic Machinery Dysregulation in Lung Cancer: Biological Roles, Therapeutic Targeting, and Combination Strategies

Bárbara Pinto iD, João P N Silva iD, Patrícia M A Silva iD, Bruno Sarmento, Juliana Carvalho-Tavares, Hassan Bousbaa iD

Pharmaceutics · 24.03.2026 · 18 (4) · 402

DOI: 10.3390/pharmaceutics18040402 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 24.03.2026. Verfasst von Bárbara Pinto und 5 weiteren Autor:innen. Beteiligte Einrichtung: UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e …. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 230 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CESPU-Cooperativa de Ensino Superior Politécnico e Universitário Crl, CESPU—Cooperativa de Ensino Superior Politécnico e Universitário Crl.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains the leading cause of cancer-related mortality worldwide and is characterized by high aggressiveness and therapeutic resistance, partly driven by mitotic dysregulation. Key mitotic regulators, including kinases such as PLK1, AURKA, AURKB, and MPS1 and kinesins such as CENPE and Eg5, are frequently overexpressed in NSCLC and SCLC, contributing to chromosomal instability, aneuploidy, and highly proliferative tumor phenotypes. Although multiple inhibitors targeting these proteins have been developed, their clinical efficacy as monotherapies has been limited. This is largely due to insufficient target dependency, adaptive resistance mechanisms, mitotic slippage, activation of compensatory pathways, and dose-limiting toxicity. This review integrates current knowledge on the physiological roles of major mitotic regulators, their dysregulation in lung tumorigenesis, and the biological and pharmacological barriers that underlie the limited success of antimitotic drugs. We further highlight preclinical and clinical evidence supporting rational combination strategies designed to enhance the antitumor activity of mitotic inhibitors while minimizing toxicity. Together, these insights underscore the need for refined therapeutic approaches that better exploit vulnerabilities in mitotic control to improve outcomes for patients with lung cancer.

Schlagwörter

Stichwörter der Autor:innen

combination therapykinase inhibitorskinesin inhibitorslung cancermitotic regulatorstherapeutic resistance

Autor:innen und Institutionen

  • UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Rua Central de Gandra 1317, 4585-116 Gandra, Po…
  • Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos 6627, Belo Horizonte 31270-901, Brazil.
  • Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, Rua Central de Gandra 1317, 4585-116 Gandra, Portugal.
  • UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), Rua Central de Gandra 1317, 4585-116 Gandra, Portugal.
  • i3S-Institute for Research and Innovation in Health, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
  • INEB-Institute of Biomedical Engineering, University of Porto, Rua Alfredo Allen 208, 4200-393 Porto, Portugal.

ORCID-Profile: Bárbara Pinto, João P N Silva, Patrícia M A Silva, Hassan Bousbaa

Förderung

  • CESPU-Cooperativa de Ensino Superior Politécnico e Universitário Crl
  • CESPU—Cooperativa de Ensino Superior Politécnico e Universitário Crl

Zitieren

APA

Pinto, B., Silva, J. P. N., Silva, P. M. A., Sarmento, B., Carvalho-Tavares, J., & Bousbaa, H. (2026). Mitotic Machinery Dysregulation in Lung Cancer: Biological Roles, Therapeutic Targeting, and Combination Strategies. Pharmaceutics, 18(4), 402. https://doi.org/10.3390/pharmaceutics18040402

Vancouver

Pinto B, Silva JPN, Silva PMA, Sarmento B, Carvalho-Tavares J, Bousbaa H. Mitotic Machinery Dysregulation in Lung Cancer: Biological Roles, Therapeutic Targeting, and Combination Strategies. Pharmaceutics. 2026;18(4):402. doi:10.3390/pharmaceutics18040402

BibTeX
@article{Pinto2026,
  author = {Pinto, Bárbara and Silva, João P N and Silva, Patrícia M A and Sarmento, Bruno and Carvalho-Tavares, Juliana and Bousbaa, Hassan},
  title = {Mitotic Machinery Dysregulation in Lung Cancer: Biological Roles, Therapeutic Targeting, and Combination Strategies},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {402},
  doi = {10.3390/pharmaceutics18040402}
}
Kostenlos starten →